NCT00001498View on ClinicalTrials.gov

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 1996

Study Completion Date

December 31, 2000

Conditions

Breast CancerBreast Neoplasms

Interventions

DRUG

methotrexate

DRUG

leucovorin

DRUG

5-fluorouracil

DRUG

cyclophosphamide

PROCEDURE

peripheral blood progenitor cell

DRUG

paclitaxel

DRUG

doxorubicin

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00001498 - A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | Biotech Hunter | Biotech Hunter